This article is more than 5 years old. Information may no longer be current.

Stryker increases board of directors

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Stryker Corporation announced an increase in the size of its board of directors to nine and the election of Roch Doliveux, PhD, as a director.

Doliveux has served since 2005 as chief executive officer and chairman of the executive committee of UCB S.A., a global biopharmaceutical company, according to a Stryker press release. He previously served as chief executive officer of Pierre Fabre Pharmaceuticals and president, of Schering-Plough International, a subsidiary of Schering-Plough Corporation.

Doliveux holds a master's degree in business from INSEAD, Fontainebleau, France, and a PhD. in veterinary medicine from Ecole Nationale Veterinaire d'Alfort, Maisons-Alfort, France.

Stephen P. MacMillan, Stryker’s chairman, president and chief executive officer, stated in the release, “Roch brings an outstanding combination of talents and experiences as a globally minded health care executive with a strong focus on patients and innovation."